Purchase this article with an account.
K. Eibenberger, S. Sacu, G. Matt, W. Buehl, R. Dunavoelgyi, C. Pruente, U. Schmidt-Erfurth; Intravitreal Ranibizumab for the Treatment of Significant Macular Edema Secondary to Acute Branch Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2010;51(13):4736.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the effect of intravitreal ranibizumab on best corrected visual acuity (BCVA) and foveal retinal thickness in eyes with clinically significant macular edema secondary to acute branch retinal vein occlusion (BRVO).
Twenty eyes of 20 consecutive patients with macular edema secondary to untreated branch retinal vein occlusion were included in this prospective clinical study. All patients received 0.5mg (0.05ml) intravitreal ranibizumab (Lucentis) at baseline. Further treatment was administered at 4-week intervals based on OCT and Visual Acuity findings. Main outcome parameters were changes in visual acuity (VA), retinal thickness (Stratus OCT and Cirrus OCT), treatment- and complication rate.
Mean BCVA increased from 4613 at baseline to 589 letters at the last follow-up visit (LV) at week 12 (p<0.01). Mean central 1mm thickness (CMT) decreased from 496133µm at baseline to 24785µm (p<0.001) at the LV by Stratus OCT and from 510156µm to 30993 (p<0.001) by Cirrus OCT. Each patient received on average 1.90.64 injections of intravitreal ranibizumab. No severe complications which are attributed to ranibizumab were observed.
Intratravitreal Ranibizumab appears to be an effective treatment option for branch retinal vein occlusion and is generally well-tolerated in patients with BRVO.
Clinical Trial: :
eudract.emea.europa.eu, Nr. 2007-002826-31
This PDF is available to Subscribers Only